<DOC>
	<DOCNO>NCT01004731</DOCNO>
	<brief_summary>The objective evaluate toxicity profile , response rate , time progression Cetuximab administer combination either Carboplatin + Gemcitabine patient advance non-small cell lung cancer positive EGFr expression .</brief_summary>
	<brief_title>Study Anti-Epidermal Growth Factor Receptor ( EGFr ) Antibody , Cetuximab , Combination With Gemcitabine/Carboplatin Patients With Stage IV Lung Cancer</brief_title>
	<detailed_description>The primary objective study evaluate safety profile Cetuximab use combination gemcitabine carboplatin patient EGFr positive , chemotherapy-naive , stage IV non-small cell lung cancer ( NSCLC ) . Also , study determine response rate patient EGFr positive chemotherapy-naive , stage IV non-small cell lung cancer ( NSCLC ) treat Cetuximab combination gemcitabine carboplatin well determine time progression patient EGFr positive chemotherapy-naive , stage IV NSCLC treat Cetuximab combination gemcitabine carboplatin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Have diagnosis histologically/cytologically confirm advanced non small cell lung cancer ( NSCLC ) . Have unidimensionally measurable and/or evaluable advanced NSCLC . Have Stage IV recurrent disease follow radiation therapy . Have ECOG performance status 01 Karnofsky performance status 80 100 study entry . Have give sign informed consent . Be least 18 year age . Have ANC great equal 1,500/mm3 , platelet great equal 100,000/mm3 , WBC great equal 3,000 mm3 , hemoglobin great equal 9 g/dL . Have total bilirubin less equal 1.5 x upper limit normal , Alk Phos , AST ALT less equal 2.5 x upper limit normal . Have serum creatinine less equal 1.5 mg/dL , calculate creatinine clearance great equal 60 cc/minute . Be disease free previously treat malignancy three year . Patients history previous basal cell carcinoma skin preinvasive carcinoma cervix exclude . Agree use effective contraception procreative potential exists . Must positive EGFr expression ( tumor tissue ) immunohistochemical assay . Have receive prior murine monoclonal antibody Cetuximab therapy . Have disease amenable curative surgery . Have receive prior chemotherapy . Have receive radiation therapy within 3 week prior first infusion Cetuximab . Have history clinically significant cardiac disease , serious arrhythmia , significant conduction abnormality , judgment PI . Have uncontrolled seizure disorder , active neurological disease , Grade 2 high neuropathy . Be pregnant breastfeeding . Have receive investigational agent ( ) within 1 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>EGFr</keyword>
	<keyword>cetuximab</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>carboplatin</keyword>
	<keyword>NSCLC</keyword>
</DOC>